RBC Capital raised the firm’s price target on HealthEquity (HQY) to $117 from $112 and keeps an Outperform rating on the shares. The company delivered strong Q1 results that were well above the Street estimates, and more importantly, put the major investor concern of continued elevated fraud expense to rest, calling out declines in fraud activity while showcasing that its new controls are working, the analyst tells investors in a research note. With regulatory tailwinds from the pending reconciliation bill, the earnings call was also highly positive, RBC added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity price target raised to $125 from $110 at BofA
- Healthequity’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- HealthEquity price target raised to $117 from $110 at Citizens JMP
- Strong Financial Performance and Strategic Growth Opportunities Drive Buy Rating for Healthequity
- Healthequity’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue